[HTML][HTML] Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19
BACKGROUND COVID-19 convalescent plasma (CCP) has been considered a treatment
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-…
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-…
[HTML][HTML] Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis
JM Kruse, A Magomedov, A Kurreck, FH Münch… - Critical Care, 2020 - Springer
Background There is emerging evidence for enhanced blood coagulation in coronavirus
2019 (COVID-19) patients, with thromboembolic complications contributing to morbidity and …
2019 (COVID-19) patients, with thromboembolic complications contributing to morbidity and …
[HTML][HTML] One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
…, H Wulf, A Ulrich, M Weiss, JM Kruse… - The Journal of …, 2022 - Am Soc Clin Investig
BACKGROUND Results of many randomized trials on COVID-19 convalescent plasma (CCP)
have been reported, but information on long-term outcome after CCP treatment is limited. …
have been reported, but information on long-term outcome after CCP treatment is limited. …
[HTML][HTML] Point-of-care lung ultrasound in COVID-19 patients: Inter-and intra-observer agreement in a prospective observational study
…, J Grune, N Hegemann, D Khadzhynov, JM Kruse… - Scientific Reports, 2021 - nature.com
With an urgent need for bedside imaging of coronavirus disease 2019 (COVID-19), this study’s
main goal was to assess inter- and intraobserver agreement in lung ultrasound (LUS) of …
main goal was to assess inter- and intraobserver agreement in lung ultrasound (LUS) of …
[HTML][HTML] Evidence for a thromboembolic pathogenesis of lung cavitations in severely ill COVID-19 patients
JM Kruse, D Zickler, WM Lüdemann, SK Piper… - Scientific Reports, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease
2019 (COVID-19) induces lung injury of varying severity, potentially causing severe acute …
2019 (COVID-19) induces lung injury of varying severity, potentially causing severe acute …
[HTML][HTML] Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients
…, A Adler, M Sigal, J Leonhardt, JM Voll, JM Kruse… - Hepatology …, 2023 - Springer
Background Increasing evidence suggests that secondary sclerosing cholangitis (SSC),
which can lead to cirrhosis or liver failure, may be a hepatobiliary long-term complication of …
which can lead to cirrhosis or liver failure, may be a hepatobiliary long-term complication of …
[HTML][HTML] Viscoelastic testing reveals normalization of the coagulation profile 12 weeks after severe COVID-19
…, A Kahl, SK Piper, KU Eckardt, T Dörner, JM Kruse - Scientific Reports, 2021 - nature.com
COVID 19 is associated with a hypercoagulable state and frequent thromboembolic
complications. For how long this acquired abnormality lasts potentially requiring preventive …
complications. For how long this acquired abnormality lasts potentially requiring preventive …
High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID
Rationale COVID-19 convalescent plasma (CCP) has been considered a treatment option
in COVID-19. Objectives To assess the efficacy of neutralizing antibody containing high-dose …
in COVID-19. Objectives To assess the efficacy of neutralizing antibody containing high-dose …
Use of hemoadsorption in patients with severe intoxication requiring extracorporeal cardiopulmonary support—a case series
…, T Slowinski, KU Eckardt, R Körner, JM Kruse - ASAIO …, 2021 - journals.lww.com
Drugs intoxications often lead to severe vasoplegia and cardiogenic shock, and VA-ECMO
represents a viable therapy option. However, as cardiopulmonary support is not contributing …
represents a viable therapy option. However, as cardiopulmonary support is not contributing …
Is the routine use of antipseudomonal antibiotics in acutely exacerbated COPD patients indicated: A retrospective analysis in 437 ICU patients.
T Schroeder, JM Kruse, F Marcy, SK Piper, C Storm… - Journal of Critical …, 2021 - Elsevier
Purpose Chronic obstructive pulmonary disease (COPD) is a risk factor for acquiring multiple
drug resistant bacteria. The main objective of this analysis was to question a beneficial …
drug resistant bacteria. The main objective of this analysis was to question a beneficial …